Our study demonstrates that both the ABO blood groups and the De Ritis ratio might represent independent predictors of tumor growth rate in patients with renal AML.
The impact of ABO mismatch on outcome following transplantation remains controversial and there are no published data regarding the impact of ABO mismatch in acute myeloid leukemia patients receiving haploidentical transplants.
The data indicated that the transcription levels of the ABO gene changed with the disease progression, suggesting its potential role in the progression of AML disease.
The distribution of ABO blood groups was determined in a multicenter study of 682 pediatric patients with acute lymphoblastic leukemia (ALL) and 224 patients with acute myeloid leukemia (AML) up to 12 years old.